Nanexa AB (publ) (NANEXA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome, Nanexa has released a report for the first quarter of 2026 and next to my studio I have the CEO David Westberg. He will give comments on results and activities as well as preclinical data. An analyst will also be present at the question time afterwards and we will of course take up a whole lot of all the questions that come in in the live chat. Welcome David. Thank you very much. Before you present, it feels like you're going from hot through hotter. How do you describe the situation right now? I think that was a really good description. We have wind in the sails. There are a lot of good activities at the lab in those areas. The collaboration we have with different companies, and we have the results that I will talk about in a bit, for Semaglutid, and that is really hot. And we have ongoing, I call it discussions, negotiations, you can use different names for it, with a number of companies. It's an intense period, and a fun period, I would say. Okay, with that, please go ahead and present, and I'll see you in a moment. Yes, okay. Well, great. Let me start with this picture of... The financial situation, you who have read the report know the figures, we have about 70 million in the cash at the beginning of the quarter. We had a positive cash flow, much thanks to the fact that these options were resolved. that came from last year's emission and we are very positive with 55 million approximately for the transactions. It gave us roughly 50 million. We made a decision yesterday where we resolved the loan by charging against shares and the reason for that is actually, I come to that actually, is that that we want to ensure that we have a very good balance sheet when we enter into real negotiations, so to speak. It also strengthens or extends our runway to about th...